A clinical study of imipenem/cilastatin sodium on intractable respiratory infections

Effect on Moderate and Severe Respiratory Infections

Abstract

Imipenem/cilastatin sodium (IPM/CS) were administered 2g/day to 34 patients with moderate or severe intractable respiratory tract infections (15 cases of pneumonia, 2 of lung abscess and 17 of bronchitis which were secondary infections or acute exacerbations of chronic respiratory disease). Thirty-three of the 34 patients had chronic respiratory disease as an underlying disorder and one had cerebral infarction. Clinical efficacy was excellent in 10 cases, good in 18, fair in 3 and poor in 3, thus the efficacy rate was 82.4%. A good clinical response was obtained in severely infected patients and old patients. MICs were measured in 12 of 42 isolated organisms, and the MICs of IPM against these organisms were lower than 3.13 μg/ml. No adverse reactions occurred, but mildly abnormal laboratory data were detected in 6 patients (17.6%). These results indicate that IPM/CS is effective against moderate or severe intractable respiratory infections.